60 DEGREES PHARMA INC (SXTP)

Company Profile

60 Degrees Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Company Info

60 DEGREES PHARMA INC

1025 Connecticut Avenue Nw, Suite 1000

WASHINGTON WASHINGTON DC

P: 12023275422

Employees: 3

Website: https://60degreespharma.com/